Track vTv Therapeutics Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

vTv Therapeutics Inc. VTVT · Stock Open vTv Therapeutics Inc. in new tab

19.69 USD
EPS
-0.44
P/B
4.04
ROE
-15.80
Beta
0.26
Target Price
55.67 USD
Loading chart...
Key Metrics
Earnings dateMarch 9, 2027
EPS-0.44
Book Value5.19
Price to Book4.04
Debt/Equity0.51
% Insiders38.829%
Estimates
Forward P/E-5.42
Forward EPS-3.87
Target Mean Price55.67

DCF valuation

Model fair value for vTv Therapeutics Inc. (VTVT)
Result
Sign in to run the valuation for VTVT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Strong buy · mean target 55.67 USD (low 42.00, high 67.00) · as of 10 Nov 2026
Low 42.00
Mean 55.67
High 67.00
Price 19.69
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

vTv Therapeutics Inc. Logo vTv Therapeutics Inc. Analysis (VTVT)

United States Health Care Official Website Stock

Is vTv Therapeutics Inc. a good investment? vTv Therapeutics Inc. (VTVT) is currently trading at 19.69 USD. Market analysts have a consensus price target of 55.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: vTv Therapeutics Inc. is expected to release its next earnings report on March 9, 2027. The market consensus estimate for Forward EPS is -3.87.

Investor FAQ

Does vTv Therapeutics Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is vTv Therapeutics Inc.?

vTv Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 9, 2027. The company currently has a trailing EPS of -0.44.

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Exchange Ticker
NMS (United States) VTVT
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 21, 2023 0.03
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion